This website uses cookies to ensure you get the best experience on our website.
- Table of Contents
, No Gclids
Disease Info Card
Charcot-marie-tooth Disease, Type Ia (disorder)
Information about Charcot-marie-tooth Disease, Type Ia (disorder): characteristics, related genes and pathways, plus antibodies you can use for research. This page is being enriched constantly, if you see some information you would like this page to include please send your suggestions to us.
Overview of Charcot-marie-tooth Disease, Type Ia (disorder)
Most recent studies have shown that Charcot-marie-tooth Disease, Type Ia (disorder) shares some biological mechanisms with atrophy, charcot-marie-tooth-disease, demyelinating-diseases, demyelinating-polyneuropathy, demyelination, hereditary-liability-to-pressure-palsies, hereditary-motor-and-sensory-neuropathies, hypertrophy, inherited-neuropathy, muscle-weakness, muscular-atrophy, nervousness, peripheral-neuropathy, polyneuropathy, polyradiculoneuropathy-chronic-inflammatory-demyelinating, sensory-neuropathy, talipes-cavus, weakness.
Among the many pathways, these few ones have gauged particular interests from scientists studying Charcot-marie-tooth Disease, Type Ia (disorder), and have been seen in publications frequently: Aging, Cell Adhesion, Cell Death, Cell Development, Cell Differentiation, Cell Proliferation, Gene Conversion, Interphase, Localization, Meiosis, Muscle Atrophy, Myelin Assembly, Myelination, Pathogenesis, Programmed Cell Death, Regeneration, Schwann Cell Development, Schwann Cell Differentiation, Schwann Cell Proliferation, Transport
Quite a number of genes have been found to play important roles in Charcot-marie-tooth Disease, Type Ia (disorder), such as CDRT1, COX10, CST7, DBNL, ENDOU, EXOSC6, GDI1, GRIP1, KIF1B, MAD2L1BP, MBP, MPZ, PES1, PMP22, PXMP2, RPLP0, S100A10. See what Boster has to offer for the research of these genes by clicking the gene name links below and view a more detailed info card/product listing for that gene.
In a later update, we will include information such as current drugs and therapy solutions as well as on-going and past clinical trials for this disease. Plesae stay updated.